NCT00302380已完成不适用
An Open Label Phase I/II Study of the Safety and Dopamine Transporter Binding Properties of C-11 Altropane in Normal Human Subjects and in Subjects With ADHD
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 300
- 主要终点
- The DAT receptor occupancy of OROS MPH and Metadate CD in adults with and without ADHD using PET scanning with C-11 Altropane.
研究概览
简要总结
The primary objective of this study is to evaluate the Binding Potential in subjects with ADHD and adults without ADHD: the intent being to demonstrate that C-11 Altropane PET can be used to differentiate adults with ADHD from healthy control subjects.
详细描述
This protocol seeks to replicate and extend our investigation of DAT binding in adults with ADHD with specific aims:
- To examine dopamine transporter (DAT) receptor binding potential in adults with ADHD, using PET scanning with 11C altropane as the ligand. We hypothesize that compared to adults without ADHD, adults with ADHD will have greater DAT binding that will not be accounted by psychiatric comorbidity or age.
- To examine the relationship of DAT binding to clinical features of ADHD. We hypothesize that DAT binding will be positively correlated with a) severity of ADHD symptoms and b) neuropsychological and interpersonal dysfunction.
- To examine the relationship between DAT binding and genetic risk factors. We hypothesize that DAT binding will be specifically associated with homozygosity of the DAT (480) gene in adults with ADHD and not with other ADHD-associated genetic markers (e.g., DRD4-7, D2, DBH).
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Months 至 55 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Signed written informed consent to participate in the study.
- •Age: 18 - 55
- •If female, non-pregnant, non-nursing with a negative serum pregnancy test and using an adequate form of birth control.
- •Supine and standing blood pressure within the range 110/60 to 150/90 mmHg.
- •Heart rate, after resting for 5 minutes, within the range 46-90 beats/min.
- •Subjects who are within 20% of the ideal weight for height
- •Right handed
- •Diagnosis of DSM-IV ADHD (current), as manifested in clinical evaluation and confirmed by structured interview (for ADHD study subjects).
- •Subjects without a diagnosis of DSM-IV ADHD (lifetime), as manifested in clinical evaluation and confirmed by structured interview (for control study subjects).
排除标准
- •Diagnosis of any psychotic disorder, bipolar disorder, severe depression, severe anxiety, or Autism. Subjects with mild mood, oppositional, conduct, and anxiety disorders may be permitted to participate if considered appropriate by the investigator
- •Scores of Baseline Scales:
- •Hamilton Depression Scale > 17 (out of a possible 67 on the 21-item scale)(Hamilton 1960) Beck Depression Inventory > 19 (out of a possible 63 on the 21-item scale)(Beck, Ward et al. 1961) Hamilton Anxiety Scale > 21 (out of a possible 56 on the 14-item scale)(Hamilton 1959)
- •History of head trauma with loss of consciousness, organic brain disorders, seizures, or neurosurgical intervention.
- •Any clinically significant chronic medical condition, in the judgement of the investigator.
- •Mental impairment as evidenced by an I.Q. <
- •Subject must be off any investigational drug for at least 4 weeks prior to the start of the study.
- •Exposure to dopamine receptor antagonists, including stimulant medications (e.g. methylphenidate) or buproprion within the previous three (3) months to the start of the study.
- •Exposure to non-stimulant ADHD medications (e.g. atomoxetine) within the previous 4 weeks to the start of the study.
- •Exposure to radiopharmaceuticals within four (4) weeks prior to PET scan.
- •Subjects receiving psychotropic medication.
- •Any clinically significant abnormality in the screening laboratory tests, vital signs, or 12-lead ECG, outside of normal limits.
- •Any woman of childbearing potential who is seeking to become pregnant or suspects that she may be pregnant.
- •Subjects with a known recent history (within the past six (6) months) of illicit drug or alcohol dependence.
结局指标
主要结局
The DAT receptor occupancy of OROS MPH and Metadate CD in adults with and without ADHD using PET scanning with C-11 Altropane.
时间窗: Subjects will lie still in the PET camera for a 90 minute period.
PET imaging will be acquired using either a HR+ or Siemens Biograph 64 PET/CT camera.
次要结局
- Genotyping(A sample of blood (2 tablespoons) will be drawn from all subjects.)
- Neuropsychological tests(Examination of cognitive-neuropsychological functioning will take approximately 2.5 hours to complete.)
研究者
相似试验
已完成
不适用
Risk of Attention Deficit Hyperactivity Disorder (ADHD) in the Children of Adults With ADHD Not Otherwise Specified (NOS)ADHDNCT00181857Massachusetts General Hospital58
已完成
4 期
Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHDAttention Deficit Hyperactivity DisorderNCT00485875Eli Lilly and Company62
已完成
不适用
Pilot Study Of Primary And Secondary Attention-Deficit/Hyperactivity Disorder Among Survivors Of Childhood CancerADHDCancerNCT01032811St. Jude Children's Research Hospital100
招募中
不适用
Target ADHD Executive Working Memory Replication StudyADHDNCT06446284Hartford Hospital130
已完成
不适用
A Novel Device for the Management of ADHDADHDNCT05777785VIZO Specs Ltd108